Sanofi (NASDAQ:SNY) announced on Thursday that it plans to repurchase €5 billion ($5.21 billion) worth of shares this year and may take a more active approach to acquisitions in the near term. The ...

Deutsche Bank has upgraded Sanofi (NASDAQ:SNY) to hold from sell, citing the company's Q4 earnings report. The investment ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Geneos Wealth Management Inc. decreased its position in Sanofi (NASDAQ:SNY – Free Report) by 2.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,223 shares of the company’s stock ...

Fifth Third Bancorp reduced its stake in Sanofi (NASDAQ:SNY – Free Report) by 9.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

Sanofi (NASDAQ:SNY – Get Free Report) was the target of unusually large options trading on Monday. Traders acquired 2,013 put options on the company. This is an increase of approximately 68% compared ...

Sanofi (NASDAQ:SNY – Free Report) – Investment analysts at Zacks Research raised their Q3 2025 EPS estimates for Sanofi in a report released on Wednesday, January 22nd. Zacks Research analyst K.

Sanofi Stock Performance NASDAQ:SNY opened at $52.48 on Friday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a twelve month low of ...

Janney Montgomery Scott LLC increased its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 5.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...